Pharma Interest Historically, Immune Design attracted a pharma acquisition by Merck in 2019, signaling high interest from large oncology players in its DCVex and GLAASTM platforms. This suggests potential for licensing or co-development deals around G100 and CMB305 to accelerate clinical progress with partner resources.

Oncology Synergy The G100 intratumoral TLR4 agonist and CMB305 cancer vaccine programs position Immune Design for combination therapies with checkpoint inhibitors and other immunotherapies. Targeting pharma and biotech partners seeking established oncology synergies could yield faster trials and shared risk.

Partnership Readiness With a lean team and modest revenue, Immune Design is likely to favor collaborations with CROs, CDMOs, or co-development partners over standalone R&D funding. Propose milestone-based licensing or staged development deals to match their resource profile.

Platform Advantage DCVex and GLAASTM provide two synergistic approaches to activate tumor-specific cytotoxic T cells, offering partners the ability to pursue multiple assets under a single collaboration. Frame conversations around platform-level partnerships, with potential for expansion into related programs.

Data-Driven Based in Seattle with exposure to a data and tech-oriented ecosystem, there is an opportunity to partner on biomarker discovery, trial design optimization, and analytic services to de-risk programs and improve readouts.